Drug updated on 4/18/2024
| Dosage Form | Injection (intravitreal; 120 mg/Ml) |
| Drug Class | Vascular endothelial growth factors and angiopoietin-2 inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD).
- Indicated for the treatment of patients with Diabetic Macular Edema (DME).
- Indicated for the treatment of patients with Macular Edema following Retinal Vein Occlusion (RVO).
Summary
- Faricimab-svoa (Vabysmo) is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration, Diabetic Macular Edema, and Macular Edema following Retinal Vein Occlusion.
- Four studies were analyzed to gather information about this drug.
- In terms of efficacy and safety in treating Diabetic Macular Edema, faricimab-svoa showed superior retinal drying, fewer injections needed, and better visual acuity outcomes compared to ranibizumab and bevacizumab.
- However, for Neovascular Age-related macular degeneration treatment, brolucizumab demonstrated superior retinal thickness reduction compared to faricimab-svoa.
- The Treat & Extend regimen of Vabysmo allows up to 16-week intervals between treatments, which could improve adherence due to its reduced injection frequency without compromising efficacy or safety.
- Detailed subgroup analyses are necessary for a comprehensive understanding of Vabysmo's comparative performance, especially regarding treatment-naive patients and longer-term outcomes beyond two years.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vabysmo (faricimab-svoa) prescribing information. | 2023 | Genentech, Inc., South San Francisco, CA |